EW
$39.99
+0.34
(+0.86%)
As of Oct 22, 2026, 8:40 PM EDT
Price history
Edgewise Therapeutics Inc (EWTX) is trading up at $39.99 (+0.86%), as of the latest quote. It is a Russell 2000 constituent in the Health Care sector.
IPO: March 26, 2021 · $16.00 offering · NASDAQ · View IPO details →
Edgewise Therapeutics Inc net income history (FY2020–FY2025)
Net income
| FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Operating income | −$17.2M | −$43.2M | −$71.7M | −$114.4M | −$158.8M | −$191.4M |
| Net income | −$17.1M | −$42.8M | −$67.6M | −$100.2M | −$133.8M | −$167.8M |
| EPS (diluted) | −$23.17 | −$1.14 | −$1.26 | −$1.57 | −$1.45 | −$1.63 |
| Balance sheet | ||||||
| Cash and equivalents | $104.9M | $15.6M | $22.0M | $86.1M | $41.7M | $61.1M |
| Total assets | $131.1M | $285.2M | $367.1M | $340.0M | $486.8M | $552.6M |
| Total liabilities | $4.34M | $10.8M | $20.4M | $21.2M | $27.6M | $30.3M |
| Shareholders' equity | −$33.4M | $274.4M | $346.7M | $318.8M | $459.2M | $522.3M |
| Cash flow | ||||||
| Operating cash flow | −$14.6M | −$33.5M | −$52.6M | −$91.9M | −$109.0M | −$143.8M |
| Capital expenditure | $203.0K | $668.0K | $5.55M | $5.75M | $1.31M | $256.0K |
| Free cash flow | −$14.8M | −$34.2M | −$58.2M | −$97.7M | −$110.3M | −$144.1M |
Net income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Operating income | −$40.4M | −$45.5M | −$46.0M | −$42.6M | −$46.9M | −$56.0M | −$54.1M | −$61.9M |
| Net income | −$34.1M | −$39.7M | −$40.8M | −$36.1M | −$40.7M | −$50.2M | −$49.0M | −$57.3M |
| EPS (diluted) | −$0.36 | −$0.42 | −$0.43 | −$0.34 | −$0.39 | −$0.47 | −$0.46 | −$0.53 |
| Balance sheet | ||||||||
| Cash and equivalents | $44.8M | $41.7M | $49.9M | $43.4M | $46.0M | $61.1M | $33.2M | $72.3M |
| Total assets | $511.3M | $486.8M | $454.4M | $613.3M | $583.5M | $552.6M | $518.5M | $479.7M |
| Total liabilities | $22.4M | $27.6M | $24.7M | $24.3M | $24.8M | $30.3M | $25.3M | $31.6M |
| Shareholders' equity | $488.9M | $459.2M | $429.7M | $589.1M | $558.6M | $522.3M | $493.2M | $448.1M |
| Cash flow | ||||||||
| Operating cash flow | −$27.4M | −$27.0M | −$37.9M | −$32.6M | −$34.8M | −$38.6M | −$42.5M | −$42.5M |
| Capital expenditure | $520.0K | $274.0K | $44.0K | $50.0K | $89.0K | $73.0K | $260.0K | $32.0K |
| Free cash flow | −$27.9M | −$27.2M | −$37.9M | −$32.6M | −$34.9M | −$38.7M | −$42.8M | −$42.5M |
From Edgewise Therapeutics Inc's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Edgewise Therapeutics Inc
- Headquarters
- Boulder, Colorado From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International